Editor's Note: Since entering the market in 1982, Louis Navellier predicted nearly every twist and turn in U.S. stocks... from Black Monday and the dot-com crash... to the Enron fraud, the housing crisis, and the rise of Nvidia in 2005. That's why the New York Times calls Louis Navellier "an icon among growth investors." Today, he's airing what could be the biggest prediction of his career – and he's putting $358 million of his own firm's money behind it.
Dear Reader,
I recently visited Mar-a-Lago...
And now I'm prepared to put my reputation on the line.
Since 1998, my proprietary system would've returned 13,126% in backtests.
(That's 13X the S&P. And 106 times the average investor, according to JP Morgan.)
There's a reason Forbes crowned me "the king of quants."
However, one investment I just uncovered could be my biggest winner of all...
It involves President Trump's plan to do whatever it takes to lead the world in artificial intelligence"...
A closely guarded, high-tech facility that Elon Musk is building in Memphis...
A paradigm-shift that could add as much as $23 trillion to the global economy...
And a new passive income stream that Elon Musk says could help you earn up to $30,000-$50,000 a year with minimal effort.
I've identified the stock at center of this megatrend – and I'm giving away its name and ticker symbol FOR FREE.
Click here to access your free pick now.
If you buy just one stock in 2026, I urge you to make it this one.
I'll also show you a 30-second demo of this technology – so you can see why Nvidia CEO Jensen Huang said, "This is superhuman. It's never been done before."
In addition, I'll provide proof that I'm investing $358 million of my own firm's money in the outcome of this radical transformation.
We're talking about a MAJOR upgrade to the artificial intelligence revolution that could make you 10X your money or more.
See the demo for yourself, right here.
Regards,
Louis Navellier
Senior Investment Analyst, InvestorPlace
P.S. By the way, a 10X gain may be a conservative estimate. In fact, if you had invested $1,000 in Nvidia when I recommended it in 2005 and held on, you would have $770,250 today. That's the size of the opportunity I'm sharing with you today. Click here to get the name and ticker symbol of the stock at the center of it all.
3 Undervalued Names Too Cheap to Ignore
Written by Nathan Reiff. Article Published: 3/7/2026.
Key Points
- Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: [Sponsorship-Ad-6-Format3]
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth.
The companies below all represent potential value plays, with value metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, including compelling dividends or promising product developments. While value opportunities may be harder to find when many companies have renewed investor attention—and some apparent value plays have deteriorating operations or other red flags—well-established, stable names can still be attractive.
Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works
Altucher: This is My Favorite FREE Starlink Pre-IPO Ticker (Ad)
In the next 3 minutes…
James Altucher – legendary investor and venture capitalist…
And someone who's known for playing his cards "close to the vest"…
Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…
Although shares have climbed more than 28% in the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45—well below the medical-industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year and has a 5% near-term upside.
Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received European Commission approval for subcutaneous injection in late 2025 and generated about $8.4 billion in sales in Q4 2025—an increase of nearly 7% year over year. Keytruda also shows promise in ovarian cancer, potentially expanding its patient base and helping Merck build revenue as it prepares for patent expiration in 2028.
Merck's portfolio is broadening. The company recently announced notable phase 3 trial results for clesrovimab-cfor (Enflonsia), an RSV treatment for young children. At the same time, Merck is reorganizing its human health business—splitting it into two units—to more easily grow non-oncology sales as Keytruda's exclusivity ends.
A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors
Campbell's (NASDAQ: CPB) shares have fallen roughly 37% over the last year as the food-and-beverage staple faced pressure from tariffs and inflation. In Q1 fiscal 2026 (ended Nov. 2, 2025), the company reported modest year-over-year declines in organic net sales and consumption, with adjusted earnings per share down about 13%. Margin improvement has been slow to materialize despite cost-saving measures.
The near term may remain challenging, and fiscal-year guidance is generally weak.
Still, Campbell's improving supply chain and strong brand loyalty—especially for its premium offerings—should offer some protection. Shifts in tariff policy could also ease near-term headwinds.
Additionally, Campbell's remains an attractive dividend play, offering a yield of 5.9%, though its payout ratio is relatively high at over 80%. Its P/E ratio of 13.5 is the lowest in about four years, factors that may persuade some investors the stock is worth the risk despite Wall Street caution.
A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place
Foodservice-distribution leader US Foods (NYSE: USFD) moved in the opposite direction of Campbell's—shares climbed about 33% over the last year. Still, its P/E of 31.6 remains reasonable by some measures compared with high-flying parts of the market.
On fundamentals, US Foods is making progress: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year over year. Better inventory management and cost-of-goods savings are helping the firm gain traction. With a planned $4 billion in capital deployment, US Foods is well positioned to sustain revenue momentum and continued adjusted-EBITDA improvement.
Analysts rate USFD a Moderate Buy (11 Buys, 2 Holds), with roughly 15% upside potential.
Wall Street Loves FIGS. So Why Do Price Targets Predict a Pullback?
Written by Jennifer Woods. Article Published: 3/2/2026.
After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has roared back to a price it hasn't touched in nearly four years. The stock has surged almost 260% over the past year, including a 58% increase in the last month alone. The rally has been driven by stronger-than-expected earnings and a wave of bullish analyst commentary. Yet despite the run-up and upbeat sentiment, the consensus 12-month price target sits at just $12.25 — roughly 30% below the current stock price. That divergence raises a key question: how much of FIGS' recovery is supported by fundamentals, and how much is momentum? A closer look at recent results and the stock's price action offers some clues.
Early investors in FIGS enjoyed a quick windfall after the company's IPO, which debuted in May 2021 at $22 per share and surged to $50 within a month. Demand for medical apparel was exceptionally strong during the COVID-19 pandemic. As the pandemic eased, however, shares reversed sharply and, within 12 months, traded below $8. In the years that followed, FIGS remained mostly range-bound in the single digits. After dipping below $4 in April 2025, the stock began another run higher — this time to the upside.
Earnings Momentum Sparks Rally
Steady gains after positive Q1 and Q2 2025 earnings set the stage, but the Q3 results released on Nov. 6 really accelerated the move. The report delivered stronger-than-expected revenue growth, solid demand across core categories, and resilient margins despite tariff headwinds. Management issued an upbeat outlook, raising full‑year guidance for net revenue and adjusted EBITDA margins. Wall Street responded, sending the stock up more than 30% over the following week and prompting Zacks Research to upgrade the rating to Strong Buy from Hold.
Altucher: This is My Favorite FREE Starlink Pre-IPO Ticker (Ad)
In the next 3 minutes…
James Altucher – legendary investor and venture capitalist…
And someone who's known for playing his cards "close to the vest"…
Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…
Key Points
- FIGS stock is up nearly 260% over the last year
- Strong earnings have fueled the rally
- Stock is trading almost 30% above the average price target
- Special Report: [Sponsorship-Ad-6-Format3]
The momentum continued after the recent Q4 earnings report on Feb. 26. The company reported a 33% jump in quarterly revenue — its strongest quarter yet — with sales topping $200 million. Management pointed to gains in active customers and higher average order values, and highlighted that scrubwear sales, which accounted for more than three-quarters of net revenue, rose 35%. International revenue also surged, increasing 55%. The quarter capped a solid year: full-year net revenue rose 14% year over year to a record $630 million. Despite tariff pressures that pressured gross margins, profitability held up, with full-year adjusted EBITDA margin beating targets by more than 200 basis points.
Earnings And Outlook Spark Analyst Support
FIGS issued an upbeat outlook, forecasting continued demand driven in part by growth in healthcare jobs, plans to expand into additional international markets, and ongoing investments across its businesses. The company also confirmed a stock buyback program. For fiscal 2026, FIGS expects net revenue growth of 10% to 12%, with further margin improvement.
Analysts responded with a wave of upgrades and target increases. Barclays moved its rating to Strong Buy from Hold, KeyCorp shifted to Overweight from Sector Weight with a $17 price target, and Goldman Sachs adjusted its view to Hold from Strong Sell. BTIG reiterated a Buy with a $15 target, and Telsey Advisory raised its target to $15 from $9.
FIGS Stock Pushes Past Price Targets
FIGS' stronger results have been the primary catalyst behind the stock's move to four‑year highs. Shares started rising even before the Q4 report, gaining nearly 14% in the session ahead of the release, and the rally intensified afterward: the stock jumped 24% on the first trading day following the results and added another 10% the next day. As of March 4, the stock was trading above $17, roughly 30% above the average 12‑month price target of $12.25 based on 10 analyst reports. That level is more than double Morgan Stanley's January $8 target and sits at or above many recent targets, including KeyCorp's $17.
The gap between bullish analyst commentary and relatively conservative price targets suggests analysts like FIGS' improving fundamentals but remain cautious about valuation. At current levels, shares trade at a price‑to‑earnings ratio near 90, implying much of the company's expected growth may already be reflected in the price. Investors are clearly applauding the turnaround, but skepticism persists over whether the stock can sustain further gains or whether a pullback could occur.
This email is a paid advertisement provided by InvestorPlace, a third-party advertiser of MarketBeat. Why did I receive this email message?.
If you have questions or concerns about your account, please feel free to contact MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103. USA..